PDF(Pubmed)
Abstract：
UNASSIGNED: Systemic immune-inflammation index (SII), a novel prognostic indicator, is being more commonly utilized in different types of cancer. This research project involved combining information from previously published studies to examine how pre-treatment SII can predict outcomes in individuals with upper tract urothelial carcinoma (UTUC). Further examination of the correlation between SII and clinical and pathological features in UTUC.
UNASSIGNED: We thoroughly chose pertinent articles from various databases including PubMed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), WanFang database, and Chinese Scientific Journal Database (VIP) until March 10, 2022.The data collected was analyzed using Stata 17.0 software (Stat Corp, College Station, TX). Subsequently, the impact of SII on the survival outcomes of UTUC patients was evaluated by combining HRs with 95% confidence intervals.
UNASSIGNED: Six included studies were finally confirmed, including 3911 UTUC patients in seven cohorts. The results showed that high SII before treatment predicted poor overall survival (HR =1.87, 95%CI 1.20-2.92, p=0.005), cancer specific survival (HR=2.70, 95%CI 1.47-4.96, P=0.001), and recurrence-free survival (HR =1.52, 95%CI 1.12-2.07, P=0.007). And the elevated SII may be related to LVI (present vs. absent) (OR=0.83, 95% CI=0.71-0.97, p=0.018), pT stage (pT ≥3 vs. < 3) (OR=1.82, 95% CI=1.21-2.72, p=0.004), and pN stage (N+ vs. N0) (OR=3.27, 95% CI=1.60-6.71, p=0.001).
UNASSIGNED: A comprehensive analysis of all included articles in this study showed that higher pretreatment SII was related to poorer survival outcomes and adverse pathological features independently.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42022316333.
UNASSIGNED: We thoroughly chose pertinent articles from various databases including PubMed, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), WanFang database, and Chinese Scientific Journal Database (VIP) until March 10, 2022.The data collected was analyzed using Stata 17.0 software (Stat Corp, College Station, TX). Subsequently, the impact of SII on the survival outcomes of UTUC patients was evaluated by combining HRs with 95% confidence intervals.
UNASSIGNED: Six included studies were finally confirmed, including 3911 UTUC patients in seven cohorts. The results showed that high SII before treatment predicted poor overall survival (HR =1.87, 95%CI 1.20-2.92, p=0.005), cancer specific survival (HR=2.70, 95%CI 1.47-4.96, P=0.001), and recurrence-free survival (HR =1.52, 95%CI 1.12-2.07, P=0.007). And the elevated SII may be related to LVI (present vs. absent) (OR=0.83, 95% CI=0.71-0.97, p=0.018), pT stage (pT ≥3 vs. < 3) (OR=1.82, 95% CI=1.21-2.72, p=0.004), and pN stage (N+ vs. N0) (OR=3.27, 95% CI=1.60-6.71, p=0.001).
UNASSIGNED: A comprehensive analysis of all included articles in this study showed that higher pretreatment SII was related to poorer survival outcomes and adverse pathological features independently.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/, identifier CRD42022316333.
摘要：
■全身免疫炎症指数（SII），一个新的预后指标，更常用于不同类型的癌症。该研究项目涉及结合先前发表的研究的信息，以检查治疗前SII如何预测上尿路尿路上皮癌（UTUC）患者的预后。进一步检查UTUC中SII与临床和病理特征之间的相关性。
■我们从包括PubMed、Embase,科克伦图书馆,WebofScience,中国国家知识基础设施(CNKI),万方数据库，和中国科学期刊数据库（VIP），直到2022年3月10日。使用Stata17.0软件（StatCorp，学院站,TX）。随后，SII对UTUC患者生存结局的影响通过结合HR和95%置信区间进行评估.
■最终确认了六项纳入研究，包括7个队列中的3911例UTUC患者。结果显示，治疗前SII高预测总生存期较差（HR=1.87，95CI1.20-2.92，p=0.005），癌症特异性生存率（HR=2.70，95CI1.47-4.96，P=0.001），无复发生存率（HR=1.52，95CI1.12-2.07，P=0.007）。SII升高可能与LVI有关(目前与不存在)(OR=0.83，95%CI=0.71-0.97，p=0.018)，pT分期(pT≥3vs.<3)(OR=1.82，95%CI=1.21-2.72，p=0.004)，和pN阶段(N+与N0)(OR=3.27,95%CI=1.60-6.71,p=0.001)。
■本研究中所有纳入的文章的综合分析表明，较高的治疗前SII与较差的生存结局和不良病理特征独立相关。
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD4202236333。
■我们从包括PubMed、Embase,科克伦图书馆,WebofScience,中国国家知识基础设施(CNKI),万方数据库，和中国科学期刊数据库（VIP），直到2022年3月10日。使用Stata17.0软件（StatCorp，学院站,TX）。随后，SII对UTUC患者生存结局的影响通过结合HR和95%置信区间进行评估.
■最终确认了六项纳入研究，包括7个队列中的3911例UTUC患者。结果显示，治疗前SII高预测总生存期较差（HR=1.87，95CI1.20-2.92，p=0.005），癌症特异性生存率（HR=2.70，95CI1.47-4.96，P=0.001），无复发生存率（HR=1.52，95CI1.12-2.07，P=0.007）。SII升高可能与LVI有关(目前与不存在)(OR=0.83，95%CI=0.71-0.97，p=0.018)，pT分期(pT≥3vs.<3)(OR=1.82，95%CI=1.21-2.72，p=0.004)，和pN阶段(N+与N0)(OR=3.27,95%CI=1.60-6.71,p=0.001)。
■本研究中所有纳入的文章的综合分析表明，较高的治疗前SII与较差的生存结局和不良病理特征独立相关。
■https://www.crd.约克。AC.英国/普华永道/，标识符CRD4202236333。
